Altogether, in vivo tumor growth studies show that LY-2584702 and BMS-777607 are orally bioavailable, brain-penetrant, and effective in combination to inhibit PTEN-deficient GBM tumor growth. This evidence concerns the gene PTEN and neoplasm.